Abstract: A method for partially publishing edits to a document is described. A first document including a first cell and a second cell is displayed on first user account on a first computing device and on a second user account. A second document including a linked version of the first cell and a linked version of the second cell is displayed. An edit of the first cell is received from the first user account and an edit of the second cell is received. In response to receiving an indication from the first user account that the edit of the first cell is to be published, the edit of the first cell is made to the linked version of the first cell, while the linked version of the second cell is unchanged so that the content of the linked version of the second cell no longer matches that of the second cell.

Abstract: An example virtualized computing system includes: a host cluster having hosts and a virtualization layer executing on hardware platforms of the hosts, the virtualization layer supporting execution of virtual machines (VMs); an orchestration control plane integrated with the virtualization layer, the orchestration control plane including a master server executing in a first VM of the VMs; guest cluster infrastructure software (GCIS) executing in the master server, the GCIS configured to create a set of objects defining a container orchestration cluster, and manage lifecycles of second VMs of the VMs based on state of the set of objects; and guest software executing in the second VMs to implement the container orchestration cluster as a guest cluster of the host cluster, the guest software having components that interface with the GCIS.

Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: Disclosed herein is a computer-implemented method comprising aggregating PFAS remediation evaluation data for a plurality of remediation options and for a plurality of predefined criteria; graphically displaying the user modifiable chart comprising the plurality of graphical representations of the aggregated PFAS remediation evaluation data, wherein: each graphical representation depicts data points visually plotted with weights, the plurality of graphical representations for the plurality of predefined criteria are visually ordered according to a rank of the plurality of predefined criteria, and the weights are based on the rank of the plurality of predefined criteria; detecting a first user input modifying the rank of at least one predefined criterion; in accordance with the first user input, automatically updating the weights of the data points; and displaying an updated user modifiable chart comprising the plurality of graphical representations of the aggregated PFAS remediation evaluation data.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: An iron-air battery including an iron electrode in contact with an anode current collector, wherein the iron electrode includes a plurality of channels; an oxygen reduction reaction electrode having a first surface facing the plurality of channels and an opposing second surface in contact with air; an oxygen evolution reaction electrode interdigitated with the plurality of channels of the iron electrode, wherein at least a portion of the oxygen evolution reaction electrode is disposed within the plurality of channels in a direction perpendicular to a plane of the oxygen reduction reaction electrode; and an electrolyte in contact with the iron electrode, the first surface of the oxygen reduction reaction electrode, the plurality of channels, and the oxygen evolution reaction electrode.

Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: Zeolite catalysts and systems and methods for preparing and using zeolite catalysts having the CHA crystal structure are disclosed. The catalysts can be used to remove nitrogen oxides from a gaseous medium across a broad temperature range and exhibit hydrothermal stability at high-reaction temperatures. The zeolite catalysts include a zeolite carrier having a silica-to-alumina ratio from about 15:1 to about 256:1 and a copper to alumina ratio from about 0.25:1 to about 1:1.

Abstract: A new and distinct raspberry variety named ‘N1237057’ is described herein. The variety resulted from selection among a population of seedlings derived from a controlled cross carried out in 2012 between NN09030 (seed parent) (not patented) and NN08021 (pollen parent) (not patented). The present variety was selected for its yield, fruit firmness, vigour and harvest season.

Abstract: Systems and methods capable for use in the development of high-speed, shape-transitioning, inward-turning inlets for air-breathing hypersonic vehicles, and inlets formed thereby. The systems and methods preferably provide for designing high-speed inlets for air-breathing hypersonic vehicles, wherein unique solutions are defined in each osculating plane of the inlet. Such systems and methods optionally provide an optimization process for tuning the post throat-shock Mach number of the inlet, and/or designs a shock-capture surface using a parallel-streamlines methodology, and/or a double cowl-lip geometry to allow flow to spill overboard.

Abstract: An example virtualized computing system includes: a host cluster having hosts and a virtualization layer executing on hardware platforms of the hosts, the virtualization layer supporting execution of virtual machines (VMs); an orchestration control plane integrated with the virtualization layer, the orchestration control plane including a master server executing in a first VM of the VMs; guest cluster infrastructure software (GCIS) executing in the master server, the GCIS configured to create a set of objects defining a container orchestration cluster, and manage lifecycles of second VMs of the VMs based on state of the set of objects; and guest software executing in the second VMs to implement the container orchestration cluster as a guest cluster of the host cluster, the guest software having components that interface with the GCIS.

Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.

Abstract: The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3?-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.

Abstract: The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.

Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.

Abstract: An example virtualized computing system includes: a host cluster having hosts and a virtualization layer executing on hardware platforms of the hosts, the virtualization layer supporting execution of virtual machines (VMs); an orchestration control plane integrated with the virtualization layer, the orchestration control plane including a master server executing in a first VM of the VMs; guest cluster infrastructure software (GCIS) executing in the master server, the GCIS configured to create a set of objects defining a container orchestration cluster, and manage lifecycles of second VMs of the VMs based on state of the set of objects; and guest software executing in the second VMs to implement the container orchestration cluster as a guest cluster of the host cluster, the guest software having components that interface with the GCIS.

Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.

Abstract: A drive circuit for an electric pump motor is provided. The drive circuit includes an inverter and a contactor. The inverter is configured to supply variable frequency current to the electric motor. The contactor is configured to supply the line frequency current to the electric motor.

Abstract: A new and distinct floricane-fruiting red raspberry, Rubus idaeus L., variety is described. The new variety is distinguished from others by, medium-large, firm, fruit that have dark red skin color and ripens late season. Fruit of the new variety appears very suitable for machine harvesting and the process fruit market.